
Carmen Aguilar Gurrieri
Carmen Aguilar obtained her degree in Biotechnology from the Autonomous University of Barcelona (UAB) in 2008, after which, funded by a Leonardo da Vinci grant, she spent several months at the European Molecular Biology Laboratory (EMBL) in Heidelberg (Germany).
In July 2009, she commenced studies for her PhD in Structural Biology at the EMBL headquarters in Grenoble (France), under the supervision of Dr Daniel Panne. In January 2015, she joined the Alternative Energies and Atomic Energy Commission (CEA) in Grenoble as a post-doctoral researcher, where she was supervised by Dr Marie-Odile Fauvarque and worked closely with Dr Winfried Weissenhorn. In October 2017 she joined IrsiCaixa’s Cell Virology and Immunology (VIC) group as a post-doctoral researcher under Dr Julià Blanco. She is currently working on the development of a new vaccination against HIV and on other infectious diseases.
Production of HIV-1-based virus-like particles for vaccination: achievements and limits.
SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity.
HIV-1 Trans-Infection Mediated by DCs: The Tip of the Iceberg of Cell-to-Cell Viral Transmission.
New emerging targets in cancer immunotherapy: the role of neoantigens.